Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Introduction. Primary transrectal multifocal prostate biopsy is the standard method for prostate cancer (PCa) verification, with the detection rate of 53 %. The purpose of the study was to improve findings of transrectal ultrasound-guided prostate biopsy (TRUS-biopsy) by its optimization due to perfusion computed tomography (PCT).Material and methods.The study included 97 patients with indications for TRUS-biopsy. All patients underwent PCT of the prostate before biopsy. Prostate cancer was detected by PCT in 43 patients. These patients underwent standard primary transrectal multifocal prostate biopsy plus additional targeted punctures from areas of increased blood flow. The results of standard and targeted punctures were compared. The McNemar criterion was used to assess the statistical significance of the differences.Results.There were no statistically significant differences in the incidence of PCa detection between standard and targeted punctures (p>0.05). However, statistically significant differences in the detection of PCa of different differentiation grades were found between standard and targeted punctures for PCa with a Gleason score of 8 (4 + 4). The detection rate of PCa with the Gleason score of 8 (4 + 4) was 5 % for standard punctures and 14 % for targeted punctures (p˂0.05). No one statistical method has been used to assess sensitivity and specificity, due to the absence of a «gold» standard (histological examination of the total amount of prostate tissue after radical prostatectomy).Conclusion.The use of primary prostate biopsy optimized with PCT findings does not allow increase in the detection rate of PCa. However, this method improves the verification of PCa with a Gleason score of 8 (4 + 4) that can influence the risk stratification and selection of further therapeutic strategy.
Introduction. Primary transrectal multifocal prostate biopsy is the standard method for prostate cancer (PCa) verification, with the detection rate of 53 %. The purpose of the study was to improve findings of transrectal ultrasound-guided prostate biopsy (TRUS-biopsy) by its optimization due to perfusion computed tomography (PCT).Material and methods.The study included 97 patients with indications for TRUS-biopsy. All patients underwent PCT of the prostate before biopsy. Prostate cancer was detected by PCT in 43 patients. These patients underwent standard primary transrectal multifocal prostate biopsy plus additional targeted punctures from areas of increased blood flow. The results of standard and targeted punctures were compared. The McNemar criterion was used to assess the statistical significance of the differences.Results.There were no statistically significant differences in the incidence of PCa detection between standard and targeted punctures (p>0.05). However, statistically significant differences in the detection of PCa of different differentiation grades were found between standard and targeted punctures for PCa with a Gleason score of 8 (4 + 4). The detection rate of PCa with the Gleason score of 8 (4 + 4) was 5 % for standard punctures and 14 % for targeted punctures (p˂0.05). No one statistical method has been used to assess sensitivity and specificity, due to the absence of a «gold» standard (histological examination of the total amount of prostate tissue after radical prostatectomy).Conclusion.The use of primary prostate biopsy optimized with PCT findings does not allow increase in the detection rate of PCa. However, this method improves the verification of PCa with a Gleason score of 8 (4 + 4) that can influence the risk stratification and selection of further therapeutic strategy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.